MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s13555-025-01453-8

Медицинская библиотека · Dermatology and therapy · 2025

Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study.

Torres Tiago, Yeung Jensen, Prajapati Vimal H, Ribero Simone, Balato Anna, Marzano Angelo Valerio, Cruz Maria João, Paiva Lopes Maria João, Lazaridou Elizabeth, Carrascosa Jose-Manuel, Alvarenga José Miguel, Farinha Pedro, Duarte Bruno, Munera-Campos Monica, Sood Siddhartha, Rankin Brian D, Ortoncelli Michela, Caccavale Stefano, Ferrucci Silvia Mariel, Pires Rosa Gilberto, Daponte Athina Ioanna, Silvi Gianmarco, Peris Ketty, Gori Niccolò, Prignano Francesca, Kolios Antonio, Herranz Pedro, Gregoriou Stamatios, Rompoti Natalia, Gkalpakiotis Spyridon, Chiricozzi Andrea

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Evaluating the real-world effectiveness, safety, and tolerability of targeted biologic and non-biologic therapies in patients with atopic dermatitis (AD) treated in routine clinical practice remains crucial. In this international, multicenter, retrospective, comparative study we aimed to evaluate the 52-week effectiveness, safety, and tolerability of dupilumab, tralokinumab, and upadacitinib in patients with AD aged ≥ 12 years.

METHODS

Effectiveness was assessed at weeks 16, 24, and 52 using Eczema Area and Severity Index (EASI) and itch Numerical Rating Scale (NRS) scores. Safety was measured via adverse events (AEs).

RESULTS

A total of 1286 treatment courses were included: 62.5% received dupilumab, 24.3% received upadacitinib, and 13.1% received tralokinumab. Upadacitinib demonstrated higher effectiveness than dupilumab and tralokinumab across all time points and most evaluated outcomes both on the overall population and the biologic-/JAKi-naïve population, including stringent treatment targets such as EASI 90 response and combined EASI 90 + itch NRS 0/1 response. While upadacitinib demonstrated superior effectiveness, it was associated with a higher incidence of AEs, both leading to and not leading to treatment discontinuation, including thromboembolic events, lipid abnormalities, and hematologic abnormalities. In contrast, conjunctivitis was the most frequently observed AE among patients receiving biologics.

CONCLUSION

This study provides a comprehensive real-world comparison of dupilumab, tralokinumab, and upadacitinib in AD, highlighting upadacitinib's superior effectiveness in achieving stringent treatment targets, both in the short and long term, but also a higher incidence of AEs. However, the considerable heterogeneity of the study population, an inherent limitation of real-world studies, must be acknowledged when interpreting these findings.

Для цитирования: Torres Tiago, Yeung Jensen, Prajapati Vimal H, Ribero Simone, Balato Anna, Marzano Angelo Valerio, Cruz Maria João, Paiva Lopes Maria João, Lazaridou Elizabeth, Carrascosa Jose-Manuel, Alvarenga José Miguel, Farinha Pedro, Duarte Bruno, Munera-Campos Monica, Sood Siddhartha, Rankin Brian D, Ortoncelli Michela, Caccavale Stefano, Ferrucci Silvia Mariel, Pires Rosa Gilberto, Daponte Athina Ioanna, Silvi Gianmarco, Peris Ketty, Gori Niccolò, Prignano Francesca, Kolios Antonio, Herranz Pedro, Gregoriou Stamatios, Rompoti Natalia, Gkalpakiotis Spyridon, Chiricozzi Andrea. Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study.. Dermatology and therapy. 2025. DOI: 10.1007/s13555-025-01453-8.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.